Gene expression is highly correlated on the chromosome level in urinary bladder cancer

Lambrou, George Ι.; Adamaki, Maria; Delakas, Dimitrios; Spandidos, Demetrios Α.; Vlahopoulos, Spiros; Zaravinos, Apostolos

doi:10.4161/cc.24673

Cited by 9 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,17 Of note, these mutations also characterize advanced nonurologic malignancies. 18 PTEN loss/inactivation has been implicated in UC development 13,16,[19][20][21][22][23] and progression 24,25 and correlated with the tumor stage and grade. 7,[16][17]19 PTEN mutations have been rarely identified in bladder UC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

Millis

Bryant

Basu

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Comprehensive molecular profiling of UC identified a large number of biomarkers aberrations that might direct treatment in conventional chemotherapies and targeted therapies, not currently recommended in this population. As a group, bladder UC exhibited higher levels of actionable biomarkers, suggesting that UC from different primary sites and non-UC are driven by different molecular pathways. These differences could have clinical implications resulting in different treatment regimens depending on the site of origin of UC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…10 Mutations of epidermal growth factor receptor (EGFR) and HER2 have been rarely observed, 11 but HER2 amplification has been described in a subset of bladder cancer patients. 12,13 Neither comprehensive simultaneous analysis of these targeted pathways nor comparison of nonbladder versus bladder UC has been performed.…”

Section: Introductionmentioning

confidence: 99%

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

Millis

Bryant

Basu

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

show abstract

“…Three studies GSE27448 30 – 32 , GSE100926 33 , and GSE61615 34 that each included the information of BC tissue and control tissues were explored. GSE27448 included: 1) GSE89figure dataset (GDS183), comprised of 40 BC samples; 2) GSE3167 dataset (GDS1479), comprised of 60 samples (9 controls and 51 BC samples); 3) GSE7476 dataset, composed of 12 samples (3 controls and 9 bladder cancer samples) and 4) GSE12630 dataset, comprised of 19 BC samples.…”

Section: Resultsmentioning

confidence: 99%

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

Mohsenzadegan

Razmi

Vafaei

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Melanoma antigen gene (MAGE)-A6 and MAGE-A11 are two of the most cancer-testis antigens overexpressed in various types of cancers. However, the clinical and prognosis value of MAGE-A6 and MAGE-A11 co-expression in the pathophysiology of the bladder is unknown. Three studies were selected from GEO databases in order to introduce the common genes that are involved in bladder cancer. Then immunohistochemical analysis for staining pattern and clinicopathological significance of suggested markers, MAGE-A6 and MAGE-A11, were performed in 199 and 213 paraffin-embedded bladder cancer with long adjacent normal tissues, respectively. A significant and positive correlation was found between both nuclear and cytoplasmic expressions of MAGE-A6 as well as expression of cytoplasmic MAGE-A11 with histological grade, PT stage, lamina propria invasion, and LP/ muscularis (L/M) involvement (all of the p-values in terms of H-score were < 0.0001). Additionally, significant differences were found between both nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes with tumor size (P = 0.007, P = 0.043, respectively), different histological grades, PT stage, LP involvement, and L/M involvement (all of the p-values for both phenotypes were < 0.0001). The current study added the value of these novel markers to the bladder cancer clinical settlement that might be considered as an admirable target for immunotherapy.

show abstract

“…Interestingly, the inhibition of ERK5, by genetic or pharmacological approaches, enhanced the antitumour efficacy of crizotinib in both in vitro and in vivo models [97], supporting the therapeutic efficacy of targeting ERK5 in neuroblastoma. Moreover, ERK5 signalling pathway effectors also appear at the top of the list of deregulated molecules in bladder cancer [98], and miRNA-143 overexpression, with concomitant repression of ERK5, functions as a tumour suppressor in human bladder cancer [99]. Furthermore, ERK5 signalling has also been implicated in human mesothelioma cell proliferation, migration, invasion, and resistance to therapy [100] and, more importantly, has been suggested as a potential beneficial therapeutic target for the development of treatment strategies in patients with malignant mesothelioma [100].…”

Section: Other Cancer Typesmentioning

confidence: 98%

The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target

Simões

Rodrigues

Borralho

2016

Drug Discovery Today

View full text Add to dashboard Cite

Gene expression is highly correlated on the chromosome level in urinary bladder cancer

Cited by 9 publications

References 46 publications

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer

The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target

Contact Info

Product

Resources

About